Skip to main content
. Author manuscript; available in PMC: 2021 Jan 1.
Published in final edited form as: Am J Transplant. 2019 Aug 13;20(1):88–100. doi: 10.1111/ajt.15533

Figure 2. Cell proliferation and CD2 expression in both proliferating and non-proliferating T cells are reduced in MLRs containing siplizumab at day 6.

Figure 2.

(A) Proliferation of CD3+ T cells in MLRs containing Siplizumab (bottom panel, 1 μg/mL) compared to control MLRs (top panel). (B) Numbers of non-proliferating (CFSEHI) and proliferating (CFSELO) T cells recovered from allogeneic MLRs at increasing drug concentrations (median [IQR]); n = 10 unique donor pairs (Friedman’s test and Dunn’s multiple comparisons tests). (C) Siplizumab median fluorescence intensity (with PE-Dazzle594 anti-human IgG Fc) in a representative sample of total, non-proliferating and proliferating T cells at increasing drug concentration, with (D) summary of the analysis (mean ± SD); n = 5 unique donor pairs. * p < 0.05 compared to No drug MLR (repeated-measures ANOVA and Dunnet’s multiple comparisons test).